Eli Lilly and Company

From WikiCorporates
(Redirected from Eli Lilly & Company)
Jump to navigation Jump to search

Flag-USA.svg

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Col. Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War, after whom the company was named. (WP)

Business Sectors


Products


Subsidiaries

Elanco Animal Health

Elanco Animal Health is a global company with a full range of products. To ensure the right operating structure for Elanco’s future growth and to maximize its value, we are reviewing strategic options, including a sale, merger, initial public offering or retention of the business, with a decision expected in mid-2018. ref, p.12

  • Jul.24.2018: Lilly to Separate Elanco Animal Health with Initial Public Offering Eli Lilly and Company today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the US Securities and Exchange Commission for a potential initial public offering of a minority ownership stake in Elanco as a separate company. The offering is expected to represent an ownership stake of less than 20%. The company expects to complete the IPO process during the second half of 2018. Elanco.

Enough Movement

The Enough Movement, the “global community” behind the advertisements, promises to tell you the truth about food. But it is a PR campaign funded by Elanco, a multinational animal drugs company which sells antibiotics for use on livestock. The 'campaign reads like a humanitarian report, offering “practical solutions” on ensuring there's enough food for everyone as the population grows. Elanco commissioned editors associated with Elite Media, a company which provides “advocacy, research and content support for lobbyists”, to author a Europe-focused version of the report. Elanco operates in 70+ countries and accounted for 13% of the veterinary pharmaceuticals market in 2015. The company, a subsidiary of pharmaceutical giant Eli Lilly and Company, was valued at $14-16bn last year. Elanco, along with other organisations with vested interests, is using advertising campaigns to downplay consumer concerns over giving antibiotics to animals. Critics say agricultural and pharmaceutical organisations are using similar tactics to steer the debate about antibiotic use on farm animals as those employed by tobacco and oil companies during public health debates about smoking and climate change. The Elanco adverts are “a classic strategy to divert the debate about residues rather than focusing on the core issue which is the selection for resistant bacteria in the live animals due to the constant exposure to those drugs on the farm.” Scientists believe giving antibiotics to animals is one of the major causes of antimicrobial resistance. Drug resistance has been dubbed one of the greatest public health threats the world faces. It is estimated to kill 700,000 people worldwide, a figure which will rise to 10 million by 2050, if no action is taken. There is now widespread scientific consensus that giving antibiotics to animals fuels resistance in bacteria which infect humans. In a 2016 report commissioned by the British govt, former economist Lord Jim O’Neill found that out of 139 academic studies, excluding those funded by industry or govt bodies, 72% supported evidence of a link between antibiotic consumption in animals and resistance in humans. Only 5% argued that there was no link. more[1] Linkback: Antibiotic Resistance

References